As part of our ongoing series focussing on available therapies in Australia, we have added a product review of the use of Secukinumab in spondyloarthritis, a five-year review.
This review discusses pharmacological properties, mechanism of action and major studies featuring Secukinumab. It also provides commentary and recommendations from Professor Peter Youssef, who is clinical associate Professor of Rheumatology at Sydney University.
Please login below to download this issue (PDF)